---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000171"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:10:27.579770+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q1 revenue $2.99B (+8% YoY); reiterates FY2026 guidance; povetacicept BLA submitted for accelerated approval

## Summary
- Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.
- CASGEVY revenue $43M; JOURNAVX revenue $29M; non-CF products drove >25% of growth.
- Completed rolling BLA submission for povetacicept in IgAN for U.S. accelerated approval; Priority Review Voucher expected to expedite review to 6 months.
- Terminated VX-522 (CF) Phase 1/2 due to persistent tolerability issues; no efficacy readout possible.
- FY2026 guidance reiterated: revenue $12.95-13.1B, combined R&D/SG&A unchanged.

## SEC filing metadata
- accession: 0000875320-26-000171
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/vrtx-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000171
- JSON: https://secwatch.observer/filing/0000875320-26-000171.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000171.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.
  - Period: Q1 2026
  - Revenue: $2.99 billion
  - Net income: $1.0 billion
  - Result: reported results
  source text: Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported Q1 2026 results: revenue $2.99 billion, net income $1.0 billion.
  - Period: Q1 2026
  - Revenue: $2.99 billion
  - Net income: $1.0 billion
  - Result: reported results
  source text: except as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2026 Financial Results — Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 — — Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported FY 2026 results: revenue $12.95 billion to $13.1 billion. Guidance reaffirmed.
  - Period: FY 2026
  - Revenue: $12.95 billion to $13.1 billion
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Vertex today reiterated full year 2026 financial guidance. Vertex's total revenue guidance of $12.95 billion to $13.1 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/0000875320-26-000171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.